|Articles|June 4, 2009
- ONCOLOGY Vol 23 No 7
- Volume 23
- Issue 7
FDA Fast-Tracks Talactoferrin/Sunitinib for Renal Cell Carcinoma
Agennix announced that talactoferrin alfa has been granted Fast Track designation by the FDA for the first-line treatment of renal cell carcinoma (RCC) in combination with sunitinib (Sutent).
Advertisement
Agennix announced that talactoferrin alfa has been granted Fast Track designation by the FDA for the first-line treatment of renal cell carcinoma (RCC) in combination with sunitinib (Sutent). The Fast Track program is designed to expedite the review of investigational drugs for the treatment of patients with serious or life-threatening diseases where there is an unmet medical need.
Articles in this issue
about 17 years ago
Prophylactic Central Lymph Node Dissection: Continued Controversyabout 17 years ago
Music Therapyabout 17 years ago
Is There a Role for LHRH Antagonists in Prostate Cancer?about 17 years ago
Important Considerations in LHRH Antagonist Therapy for Prostate Cancerabout 17 years ago
The Role of LHRH Antagonists in the Treatment of Prostate CancerAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
2
The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?
3
Developers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer
4
Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma
5